

Curriculum Vitae
Mei-Hsuan Lee (李美璇), Ph.D.

Address

Institute of Clinical Medicine
National Yang Ming Chiao Tung University
155 Li-Nong Street, Section 2, Peitou
Taipei 112, Taiwan

Email: meihlee@nycu.edu.tw ; meihlee@ntu.edu.tw

Current Position

2021-present, Professor, Institute of Clinical Medicine, National Yang Ming Chiao Tung University
2021-Deputy Dean of Research and Development, National Yang Ming Chiao Tung University

Education

2004-2010, Ph.D., Graduate Institute of Epidemiology, College of Public Health, National Taiwan University

Postgraduate Information and Research Experiences

2020-2021, Professor, Institute of Clinical Medicine, National Yang-Ming University
2016-2020, Associate Professor, Institute of Clinical Medicine, National Yang-Ming University
2012-2016, Assistant Professor, Institute of Clinical Medicine, National Yang-Ming University
2010-2012, Postdoctoral Fellow, Genomics Research Center, Academia Sinica, Taipei, Taiwan
2015, Visiting Scholar, Genomics Research Center, Academia Sinica, Taipei, Taiwan
2016, Visiting Scholar, University of Tokyo, Japan
2018, Visiting Scholar, National Cancer Institute, United States

Honors

2010 the 20th Wang Ming-Ning Award, Wang Ming-Ning Memorial Foundation (as a member of the REVEAL-HBV study group) (財團法人王民寧先生紀念基金會傑出貢獻獎)
2011 the 17th Professor Kung-Pei Chen Memorial Award (陳拱北預防醫學基金會公共衛生優秀論文獎)
2011 the 21st Wang Ming-Ning Award, Wang Ming-Ning Memorial Foundation (財團法人王民寧先生紀念基金會博士論文獎)

2012 Outstanding Postdoctoral Fellow, Genomics Research Center, Academia Sinica (中央研究院基因體研究中心傑出博士後研究員)

2012 Young Investigator Award, Asian Pacific Association for the Study of the Liver (APASL) (亞太肝臟醫學會年輕學者獎)

2013 the 27th Professor Sung Juei-Low's Academic Prize for Excellent Research (宋瑞樓教授學術基金會優秀論文獎)

2013 the Award for Outstanding Contributions in Science and Technology, Executive Yuan (行政院傑出科技貢獻獎)

2015 Invited General Participants, the Frontiers of Science Programmes-FoS, Marseille, France

2016 Ten Outstanding Young People (十大傑出青年)

2020 Tien-Te Lee Award-Youth Medical Technology Award (第 16 屆永信李天德醫藥科技獎-青年醫藥科技獎)

2021 Outstanding Research Award, Ministry of Science and Technology (科技部傑出研究獎)

2022 Excellence in Teaching Award, College of Medicine, National Yang Ming Chiao Tung University (醫學院優良教學教師)

Publication List

Published papers in peer-reviewed journals

1. Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, Chen PJ, Wang LY, You SL, Chen WJ, and Chen CJ*. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. *J Clin Oncol*, 2010; 28: 4587-93.
2. Lee MH, Yang HI, Wang CH, Jen CL, Yeh SH, Liu CJ, You SL, Chen WJ, and Chen CJ*. Hepatitis C virus infection and increased risk of cerebrovascular disease. *Stroke*, 2010; 41:2894-900.
3. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, You SL, Iloeje UH, and Chen CJ*. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. *Gastroenterology*, 2010; 139: 474-82.
4. Wang CH*, Chen CJ, Lee MH, Yang HI, and Hsaio CK. Chronic hepatitis B infection and risks of atherosclerosis-related mortality: a 17-year follow-up study based on 22,472 residents in Taiwan. *Atherosclerosis*, 2010; 211: 624-9.
5. Lee MH, Yang HI, Jen CL, Yeh SH, Liu CJ, You SL, Sun CA, Wang LY, Chen WJ, and Chen CJ*. Community and personal risk factors for HCV infection: a survey of 23,820 residents in Taiwan. *Gut*, 2011; 60: 688-94.

6. Lee MH, Yang HI, Wang CH, Chen CJ*. Response to Letter by Lin et al Regarding article, "Hepatitis C virus infection and increased risk of cerebrovascular disease". *Stroke*, 2011;42:E390-E1.
7. Chen CJ* and Lee MH. Early diagnosis of hepatocellular carcinoma by multiple microRNAs: validity, efficacy and cost-effectiveness. *J Clin Oncol*, 2011; 29; 4745-7.
8. Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, Iloeje UH, Chen CJ*. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. *J Clin Oncol*, 2011;29:3643-50.
9. Yang HI, Hung HL, Lee MH, Liu J, Jen CL, Su J, Wang LY, Lu SN, You SL, Iloeje UH, Chen CJ*. Incidence and determinants of spontaneous seroclearance of HB e antigen and DNA in patients with chronic hepatitis B. *Clin Gastroenterol Hepatol*, 2011; 10: 527-34.
10. Yang HI, Lee MH, Chen CJ*. Prediction of hepatocellular carcinoma risk in chronic hepatitis B and C: review of findings in R.E.V.E.A.L.-HBV/HCV study. *J Clin Hepatol*, 2011; 27:357-62. (in Chinese)
11. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ*. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases : a community-based long-term prospective study. *J Infect Dis*, 2012 ; 206 : 469-77.
12. Lee MH, Yang HI, Chen CJ*. Long-term health outcomes of chronic hepatitis C patients: A review of findings from REVEAL-HCV cohort study. *Biomedicine*, 2012; 2 (3): 99-107.
13. Liao SF, Yang HI, Lee MH, Chen CJ, Lee WC*. Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan. *PLoS One*, 2012; 7 (4): e34779.
14. Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, You SL, Wang LY, Chen CJ*. Prediction model of long-term liver cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scoresintegrating host and hepatitis B virus profiles. *Hepatology*, 2013;58 (2):546-554.
15. Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, Wang LY, You SL, Hsiao CK, Yang HI, Chen CJ*. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. *J Hepatol*,

2013;58 (5): 853-60.

16. Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, Lu SN, Liu J, Chen CJ*. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. *PLoS One*, 2013; 8 (4) : e61448.
17. Loomba R, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, Iloeje UH, Su J, You SL, Brenner D, Chen CJ*. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. *Clin Gastroenterol Hepatol*, 2013; 11 (12): 1636-1645.
18. McEwan P*, Ward T, Chen CJ, Lee MH, Yang HI, Kim R, L'Italien G, Yuan Y. Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection. *Value in Health*, 2013; 3: 5-11.
19. Lee MH*, Lu SN*, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L'Italien G, Chen CJ. Development and validation of a clinical scoring system for predicting risk of hepatocellular carcinoma in asymptomatic individuals seropositive for anti-HCV antibodies. *PLoS One*, 2014: e94760.
20. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, L'Italien G, Chen CJ*, Yuan Y. Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. *International Journal of Cancer*, 2014; 135: 1119-1126.
21. Lee MH, Yang HI, Yuan Y, L'Italien G, Chen CJ*. Epidemiology and natural history of hepatitis C virus infection. *World Journal of Gastroenterology*, 2014; 20: 9270-9280.
22. Yang HI, Lee MH, Liu J, Chen CJ*. Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B. *World Journal of Gastroenterology*, 2014; 20: 6244-6251.
23. Liu J, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, Lu SN, Wang LY, You SL, Hsiao CK, Chen CJ*. Distinct seromarkers predict different milestones of chronic hepatitis B progression. *Hepatology*, 2014 ; 60 (1) : 77-86.
24. Chen CJ*, Hsu WL, Yang HI, Lee MH, Chen HC, Chien YC, You SL. Epidemiology of virus infection and human cancer. *Recent Results Cancer Research*, 2014; 193: 11-32.
25. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrla-Utermann R, Wang LY, You SL, Hsiao CK, Chen PJ, Chen CJ*. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. *Gut*, 2014; 63 (10): 1648-57.

26. Hsu CE, Chiu YC, Tsai SH, Lin TC, Lee MH*, Huang KC. Trochanter stabilising plate improves treatment outcomes in AO/OTA 31-A2 intertrochanteric fractures with critical thin femoral lateral walls. *Injury*, 2015; 46 (6): 1047-53.
27. Chiang CJ, Yang YW, Chen JD, You SL, Yang HI, Lee MH, Lai MS, Chen CJ*. Significant reduction in end-stage liver diseases burden through national viral hepatitis therapy program in Taiwan. *Hepatology*, 2015; 61 (4): 1154-62.
28. Liu J, Tseng TC, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, Lu SN, Wang LY, You SL, Chen PJ, Chen CJ*, Kao JH. Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: external validation of a scoring system. *J Infect Dis*, 2015; 211 (10): 1566-73.
29. Chen CJ*, Lee MH, Liu J, Yang HI. Hepatocellular carcinoma risk scores: ready to use in 2015? *Hepatic Oncology*, 2015; 2 (1): 1-4.
30. Lee MH*, Yang HI, Lu SN, Lin YJ, Jen CL, Wong KH, Chan SY, Chen LC, Wang LY, Yuan Y, L'Italien G, Chen CJ*. Polymorphisms near the IFNL3 gene associated with HCV RNA spontaneous clearance and hepatocellular carcinoma risk. *Scientific Reports*, 2015; 5: 17030.
31. Chen HY, Yu SL, Ho BC, Su KY, Hsu YC, Chang CS, Li YC, Yang SY, Hsu PY, Ho H, Chan YH, Chen CY, Yang HI, Hsu CP, Yang TY, Chen KC, Hsu KH, Tseng JS, Hsia JY, Chuang CY, Yuan S, Lee MH, Liu CH, Wu GI, Hsiung CA, Chen YM, Wang CL, Huang MS, Yu CJ, Chen KY, Su WC, Chen HW, Chen J JW, Chen CJ, Chang GC*, Yang PC*, Li KC*. R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability. *J Clin Oncol*, 2015; 33 (20): 2303-10.
32. Chien J, Liu J, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, You SL, Yang HI, Chen CJ*. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis. *J Gastroenterol Hepatol*, 2016; 31 (12): 1971-1977.
33. Liu J, Yang HI, Lee MH, Jen CL, Hu HH, Lu SN, Wang LY, You SL, Huang YT, Chen CJ*. Alcohol drinking mediates the association between polymorphisms of ADH1B and ALDH2 and hepatitis B related hepatocellular carcinoma. *Cancer Epidemiology Biomarkers and Prevention*, 2016; 25 (4): 693-9.
34. Hwang YT*, Freeman JR, Yang HI, Liu J, Lee MH, Chen CJ. Mediation effect of hepatitis B and C on mortality. *European Journal of Epidemiology*, 2016; 31 (6): 625-33.

35. Hu HH, Liu J, Lin YL, Luo WS, Chu YJ, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY, You SL, Yang HI*, Chen CJ. The rs2296651 (S267F) variant on NTCP (*SLC10A1*) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B. *Gut*, 2016; 65 (9): 1514-21.
36. Yang HI, Tseng TC, Liu J, Lee MH, Liu CJ, Su TH, Batrla-Utermann R, Chan HL, Kao JH, Chen CJ*. Incorporating serum levels of hepatitis B surface antigen or omitting level of hepatitis B virus DNA does not affect calculation of risk for hepatocellular carcinoma in patients without cirrhosis. *Clin Gastroenterol Hepatol*, 2016;14 (3):461-468.
37. Hwang YT*, Yang HI, Liu J, Lee MH, Freeman J, Chen CJ. Mediation analysis of hepatitis B and C in relation to hepatocellular carcinoma risk. *Epidemiology*, 2016; 27 (1): 14-20.
38. Younossi ZM*, Stepanova M, Chan H LY, Lee MH, Yu ML, Dan YY, Choi MS, Chan HL. Patient-reported outcomes in Asian patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. *Medicine*, 2016; 95 (9): e2702.
39. Liu J, Yang HI, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, You SL, Chen CJ*. Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression. *Hepatology*, 2016; 64 (2): 381-9.
40. Rao HY, Li H, Chen H, Shang J, Xie Q, Gao ZL, Li J, Sun YT, Jiang JN, Wang L, Zhao LF, Zhang LJ, Yang WB, Niu JQ, Gong ZJ, Gong GZ, Yang RF, Lee MH, Wei L*. Real world treatment patterns and clinical outcomes of HCV treatment-naïve patients in China: an interim analysis from the CCgenos study. *J Gastroenterol Hepatol*, 2016; 32 (1): 244-252.
41. Hsu CE, Huang KC, Lin TC, Tong KM, Lee MH*, Chiu YC*. Integrated risk scoring model for predicting dynamic hip screw treatment outcome of intertrochanteric fracture. *Injury*, 2016; 47 (11): 2501-2506.
42. Lin YJ, Shaw TW G, Yang HI, Lu SN, Jen CL, Wang LY, Wong KH, Chan SY, Yuan Y, L'Italien G, Chen CJ, Lee MH*. Chronic hepatitis C virus infection and the risk for diabetes: a community-based prospective study. *Liver International*, 2017; 37 (2): 179-186.
43. Chen MH, Chen MH, Liu CH, Tsai CY, Huang DF, Lin HY, Lee MH*, Huang YH*. Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. *J Infect Dis*, 2017; 215 (4): 566-573.
44. Huang CF, Yeh ML, Huang CI, Lin YJ, Tsai PC, Lin ZY, Chan SY, Chen SC, Yang HI,

- Huang JF, Lu SN, Dai CY, Jen CL, Y Yuan, G L'Italien, Wang LY, Lee MH*, Yu ML*, Chuang WL, Chen CJ. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. *Oncotarget*, 2017; 8 (27): 43925-43933.
45. Lee MH, Hsiao TI, Subramaniam SR, Le AK, Vu VD, Trinh HN, Zhang J, Jin M, Wong VWS, Wong GLH, Nguyen MH. HCV genotype 6 increased the risk for hepatocellular carcinoma among Asian patients with liver cirrhosis. *American Journal of Gastroenterology*, 2017; 112 (7): 1111-1119.
46. Lai TH, Lee MH, Yang, HI, You SL, Lu SN, Wang LY, Yuan Y, L'Italien G, Chien KL, Chen CJ. Hepatitis C Viral Load, Genotype and Increased Risk of Developing End-Stage Renal Disease: the REVEAL-HCV Study. *Hepatology*, 2017; 66 (3): 784-793.
47. Lee MH*, Huang CF, Lai HC, Lin CY, Dai CY, Liu CJ, Wang JH, Huang JF, Su WP, Yang HC, Kee KM, Yeh ML, Chuang PH, Hsu SJ, Huang CI, Kao JT, Chen CC, Chen SH, Jeng WJ, Yang HI, Yuan Y, Lu SN, Sheen IS, Liu CH, Peng CY, Kao JH, Yu ML, Chuang WL, Chen CJ. Clinical efficacy and post-treatment seromarkers associated with the risk of hepatocellular carcinoma among chronic hepatitis C patients. *Scientific Reports*, 2017; 7 (1): 3718.
48. Lai TH, Lee MH, Yang HI, You SL, Lu SN, Wang LY, Yuan Y, L'Italien G, Chien KL, Chen CJ. High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease. *Kidney International*, 2017; 92 (3): 703-709.
49. Chu YJ, Yang HI, Wu HC, Liu J, Wang LY, Lu SN, Lee MH, Jen CL, You SL, Santella RM, Chen CJ. Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. *International Journal of Cancer*, 2017; 141 (4): 711-720.
50. Chen CH, Lee CM, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Wang JH, Lee MH, Peng CY. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. *Oncotarget*, 2017; 8 (54): 92431-92441.
51. Liu J, Hu HH, Lee MH, Korenaga M, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, Mizokami M, Chen CJ, Yang HI. Serum levels of M2BPGi as short-term predictors of hepatocellular carcinoma in chronic hepatitis B. *Scientific Reports*, 2017; 7 (1): 14352.

52. Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, Workneh A, Njouom R, Al Ghazzawi I, Abdulla M, Kaliaskarova KS, Owusu-Ofori S, Abdelmageed MK, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen DS, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Gamkrelidze I, Garcia V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Hamoudi W, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John AK, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Malu AO, Mateva L, Mitova R, Morović M, Murphy K, Mustapha B, Nde H, Nersesov A, Ngige E, Njaya O, Nonković D, Obekpa S, Oguiche S, Okolo EE, Omede O, Omuemu C, Ondoa P, Phillips RO, Prokopenko YN, Razavi H, Razavi-Shearer D, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Simonova M, Su TH, Sultan K, Tan SS, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Wani HU, Wong VWS, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Razavi-Shearer K. Historical epidemiology of hepatitis C virus in select countries: Volume 4. *Journal of Viral Hepatitis*, 2017; Suppl 2:8-24.
53. Chan HLY, Chen CJ, Omede O, Al Qamish J, Al Naamani K, Bane A, Tan SS, Simonova M, Cardenas I, Derbala M, Akin O, Phillips RO, Abdelmageed MK, Abdulla M, Adda D, Al Baqali A, Al Dweik N, Al Ejji K, Al Ghazzawi I, Al Kaabi S, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Chen DS, Chen PJ, Chien RN, Chuang WL, Cuellar D, Elbardiny AA, Estes C, Farag E, Fung J, Gamkrelidze I, Garcia V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Hamoudi W, Himatt SM, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John AK, Kaliaskarova KS, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Maaroufi A, Malu AO, Mateva L, Mitova R, Mohamed R, Morović M, Murphy K, Mustapha B, Nersesov A, Ngige E, Njouom R, Njaya O, Nonković D, Obekpa S, Oguiche S, Okolo EE, Omuemu C, Ondoa P, Opare-Sem O, Owusu-Ofori S, Prokopenko YN, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Su TH, Sultan K, Tchernev K, Tsang

OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Vince A, Wani HU, Wong VWS, Workneh A, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Nde H. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4. *Journal of Viral Hepatitis*, 2017; Suppl 2: 25-43.

54. Chen DS, Hamoudi W, Mustapha B, Layden J, Nersesov A, Reic T, Garcia V, Rios C, Mateva L, Njoya O, Al-Busafi SA, Abdelmageed MK, Abdulla M, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Ghazzawi I, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, AlBadri M, Al-Romaihi HE, Ampofo W, Antonov K, Anyaika C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Fung J, Gamkrelidze I, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Himatt SM, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jeleu D, John AK, Kaliaskarova KS, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Maaroufi A, Malu AO, Mitova R, Mohamed R, Morović M, Murphy K, Nde H, Ngige E, Njouom R, Nonković D, Obekpa S, Oguche S, Okolo EE, Omede O, Omuemu C, Ondo P, Opare-Sem O, Owusu-Ofori S, Phillips RO, Prokopenko YN, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Redae B, Rinke de Wit T, Robbins S, Roberts LR, Sanad SJ, Sharma M, Simonova M, Su TH50, Sultan K, Tan SS, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Vince A, Wani HU, Wong VWS, Workneh A, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Schmelzer JD. Strategies to manage hepatitis C virus infection disease burden: Volume 4. *Journal of Viral Hepatitis*, 2017; Suppl 2:44-63.
55. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *Lancet Gastroenterol Hepatol*, 2017; 2 (3):161-176.
56. Lee PC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lee MH, Hou MC, Lee FY, Lin HC, Huang YH. Validation of the ALBI grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. *Liver International*, 2018; 38 (2): 321-330.
57. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. *Lancet Gastroenterol Hepatol*, 2018; 3 (6): 383-403.

58. Lee MH*, Huang YH, Chen HY, Khor C SS, Chang YH, Lin YJ, Jen CL, Lu SN, Yang HI, Nishida N, Sugiyama M, Mizokami M, Yuan Y, L'Italien G, Tokunaga K, Chen CJ. Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by HCV genotypes: a genome-wide association study. *Hepatology*, 2018; 67 (2): 651-661.
59. Younossi ZM*, Stepanova M, Chan H LY, Lee MH, Yu ML, Dan YY, Choi MS, Chan HL. Impact of Ledipasvir/Sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. *Journal of Viral Hepatitis*, 2018; 25 (3): 228-235.
60. Chen MH, Lee MH, Liao HT, Chen WS, Lai CC, Tasi CY*. Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment. *Clinical Rheumatology*, 2018; 37 (2): 429-438.
61. Chu YJ, Yang HI, Wu HC, Lee MH, Liu J, Wang LY, Lu SN, Jen CL, You SL, Santella RM, Chen CJ*. Aflatoxin B1 exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption. *European Journal of Cancer*, 2018; 94: 37-46.
62. Lee MH*. Risk of hepatocellular carcinoma for patients treated with direct-acting antivirals: Steps after hepatitis C virus eradication to achieve elimination. *Translational Gastroenterology and Hepatology*, 2018; 3: 15.
63. Kutsenko A, Le AK, Lee MH, Lin YJ, Nguyen P, Trinh Sm Dang H, Nguyen MH*. Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors. *Scientific Reports*, 2018; 8: 7164.
64. Chen VL, Yeh ML, Le AK, Jun M, Saeed WK, Yang JD, Huang CF, Lee HY, Tsai PC, Lee MH, Giama N, Kim NG, Nguyen PP, Dang H, Ali HA, Zhang N, Huang JF, Dai CY, Chuang WL, Roberts LR, Jun DW, Lim YS, Yu ML, Nguyen MH*. Antiviral therapy is associated with improved survival but underutilized in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. *Aliment Pharmacol Ther*, 2018; 48 (1): 44-54.
65. Lin YJ, Chang CL, Chen LC, Hu HH, Liu J, Korenaga M, Huang YH, Jen CL, Su CY, Nishida N, Sugiyama M, Lu SN, Wang LY, Yuan Y, L'Italien G, Yang HI, Mizokami M, Chen CJ, Lee MH*. A Glycomarker for short-term prediction of hepatocellular carcinoma: A longitudinal study with serial measurements. *Clinical and Translational Gastroenterology*, 2018; 9 (9): 183.

66. Hu HH, Liu J, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY, Quan Y, Xia NS, Chen CJ, Chen PJ, Yang HI*. Level of hepatitis B (HB) core antibody associates with seroclearance of HBV DNA and HB surface antigen in HB e antigen-seronegative patients. *Clin Gastroenterol Hepatol*, 2019; 17 (1): 172-181.
67. Nguyen MH*, Yang HI, Le A, Henry L, Nguyen N, Lee MH, Zhang J, Wong C, Wong C, Trinh H. Reduced incidence of hepatocellular carcinoma with tenofovir in chronic hepatitis B patients with and without cirrhosis - a propensity score matched study. *J Infect Dis*, 2019; 219 (1): 10-18.
68. Estevez J, Yang JD, Leong J, Nguyen P, Giam NH, Zhang N, Ali HA, Lee MH, Cheung R, Roberts L, Schwartz M, Nguyen MH*. Clinical features associated with survival outcome in African American patients with hepatocellular carcinoma. *American Journal of Gastroenterology*, 2019; 114 (1): 80-88.
69. Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH, Peng CY*. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy. *J Gastroenterol Hepatol*, 2019; 34 (2): 442-449.
70. Trinh S, Le AK, Chang ET, Hoang J, Jeong D, Chung M, Lee MH, Wang U, Henry L, Cheung R, Nguyen MH*. Changes in renal function in patients with chronic HBV infection treated with tenofovir disoproxil fumarate vs entecavir. *Clin Gastroenterol Hepatol*, 2019; 17 (5): 948-956.
71. Liu J, Hu HH, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY, Yuan Q, Xia NS, Sugiyama M, Nishida N, Mizokami M, Chen CJ, Chen PJ, Yang HI*. Association between high levels of hepatitis B core antibody and seroclearance of hepatitis B e antigen in individuals with chronic hepatitis B virus infection. *Clin Gastroenterol Hepatol*, 2019; 17 (7): 1413-1415.
72. Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamura M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH*; REAL-C Investigators. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. *Hepatology International*, 2019; 13 (5): 587-598.

73. Tsai DH, Lee MH, Chen DS, Liaw YF, PC Yang, Huang YH, Chen CJ*. Taiwan's health-care system and administration are independent of China. *Lancet*, 2019; 394 (10208): 1516.
74. Lee MH*, Gao YT, Huang YH, McGee EE, Lam T, Wang B, Shen MC, Rashid A, Pfeiffer RM, Hsing AW, Koshiol J*. A Metallomic approach to assess associations of serum metal levels with gallstones and gallbladder cancer. *Hepatology*, 2020; 71 (3): 917-28.
75. Liu CH, Lee MH, Lin JW, Liu CJ, Su TH, Tseng TC, Chen PJ, Chen DS, Kao JH*. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct acting antivirals. *Journal Hepatol*, 2020; 72 (5): 839-846.
76. Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai CY, Huang JF, Yang HI, Lee MH, Jung Jun M, Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH*; REAL-C Investigators, Ahn SB, Azuma K, Dohmen K, Yoon Jeong J, Jung JH, Kajiwarra E, Kato M, Kawano A, Koyanagi T, Ooho A, Park SH, Satoh T, Shimoda S, Song DS, Takahashi K, Yeh ML, Yoon EL. HCV cure rates are reduced in patients with active but not inactive hepatocellular carcinoma - a practice implication. *Clin Infect Dis*, 2020; 71 (11): 2840-2848.
77. Chien LH, Chen CH, Chen TY, Chang GCm Tsai YH, Hsiao CF, Chen KY, Su WC, Wang WC, Huang MS, Chen YM, Chen CY, Liang SK, Chen CY, Wang CL, Lee MH, Chung RH, Tsai FY, Hu JW, Katki HA, Chatterjee N, Chanock SJ, Rothman N, Lan Q, Yang PC, Chen CJ, Chang IS, Hsiung CA*. Predicting lung cancer occurrence in never-smoking females in Asia: TNSF-SQ, a prediction model. *Cancer Epidemiol Biomarkers Prev*, 2020; 29 (2): 452-459.
78. Young SH, Chau GY, Lee IC, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Lee MH*, Huang YH*. Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. *Journal of the Formosan Medical Association*, 2020; 119 (1): 218-229.
79. Huang C, Chen SP, Huang YH, Chen HY, Wang YF, Lee MH*, Wang SJ*. HLA class I alleles are associated with clinic-based migraine and increased risk of chronic migraine and medication overuse. *Cephalalgia*, 2020; 40 (5): 493-502.

80. Huang YH, Khor SS, Zhen X, Chen HY, Chang YH, Chu HW, Wu PE, Lin YJ, Liao SF, Shen CY, Tokunaga K*, Lee MH*. A high-resolution *HLA* imputation system for the Taiwanese population: a study of the Taiwan Biobank. *The Pharmacogenomics Journal*, 2020; 20: 695-704.
81. Wu PF, Hang JF, Strong C, Chen SJ, Lin LY, Chen SS, Lai CR, Ku SWW, Lee MH*. Anal human papillomavirus and its associations with abnormal anal cytology among men who have sex with men. *Scientific Reports*, 2020; 10: 3165.
82. Huang WY, Tsai CL, Que JY, Lo CH, Lin YJ, Dai YH, Yang JF, Shen PC, Lee MH*, Cheng JCH*. Development and validation of a nomogram for patients with non-metastatic BCLC stage C hepatocellular carcinoma after stereotactic body radiotherapy. *Liver Cancer*, 2020; 9 (3): 326-337.
83. Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH, Peng CY. On-treatment changes in FIB-4 and 1-year FIB-4 values help identify patients with chronic hepatitis B receiving entecavir therapy who have the lowest risk of hepatocellular carcinoma. *Cancers*, 2020; 12 (5): 1177.
84. Raghav L, Chang YH, Hsu YC, Li YC, Chen CY, Yang TY, Chen KC, Hsu KH, Tseng JS, Chuang CY, Lee MH, Wang CL, Chen HW, Yu SL, Su SF, Yuan SS, Chen JJW, Ho SY, Li KC, Yang PC, Chang GC, Chen HY. Landscape of mitochondria genome and clinical outcomes in stage 1 lung adenocarcinoma. *Cancers*, 2020; 12 (3): 755.
85. Jackson SS, Adami HO, Andreotti G, Beane-Freeman LE, Berrington de González A, Buring JE, Fraser GE, Freedman ND, Gapstur SM, Gierach G, Giles GG, Grodstein F, Hartge P, Jenab M, Kirsh V, Knutsen SF, Lan Q, Larsson SC, Lee IM, Lee MH, Liao LM, Milne RL, Monroe KR, Neuhauser ML, O'Brien KM, Petrick JL, Purdue MP, Rohan TE, Sandin S, Sandler DP, Sawada N, Shadyab AH, Simon TG, Sinha R, Stolzenberg-Solomon R, Tsugane S, Weiderpass E, Wolk A, Yang HI, Zheng W, McGlynn KA, Campbell PT, Koshiol J. Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project. *J Hepatol*, 2020; 73: 863-872.
86. Petrick JL, Florio AA, Koshiol J, Pfeiffer RM, Yang B, Yu K, Chen CJ, Yang HI, Lee MH, McGlynn KA. Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies. *Int J Cancer*, 2020; 147 (10): 2743-2753.
87. Huang YH, Liao SF, Khor, SS, Lin YJ, Chen HY, Chang YH, Huang YH, Lu SN, Lee HW,

- Ko WY, Huang C, Liu PC, Chen YJ, Wu PF, Chu HW, Wu PE, Tokunaga K, Shen CY, Lee MH*. Large-scale genome-wide association study identifies *HLA* class II variants associated with chronic HBV infection: a study from Taiwan Biobank. *Aliment Pharmacol Ther*, 2020; 52 (4): 682-691.
88. Lee MH* and Huang YH. Editorial: genome-wide association for developing chronic hepatitis B-author's reply. *Aliment Pharmacol Ther*, 2020; 52 (6): 1085-1086.
89. Lee MH*, Huang YH, Coghill AE, Liu Z, Yu KJ, Hsu WL, Chien YC, Wang CP, Chen TC, Chen CJ, Hildesheim A. Epstein-Barr virus (EBV) based nasopharyngeal carcinoma (NPC) risk prediction scores are elevated in NPC multiplex family members compared to the general population in Taiwan. *J Infect Dis*, 2021; 223 (3): 441-444.
90. Chen CJ, You SL, Hsu WL, Yang HI, Lee MH, Chen HC, Chen YY, Liu J, Hu HH, Lin YJ, Chu YJ, Huang YT, Chiang CJ, Chien YC. Epidemiology of virus infection and human cancer. *Recent Results Cancer Res*, 2021; 217: 13-45.
91. Chen CY, Huang CF, Cheng PN, Tseng KC, Lo CC, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Huang JF, Yang CC, Hu JT, Lin CW, Chen CT, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Mo LR, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Liu CJ, Dai CY, Kao JH, Chuang WL, Lin HC, Yu ML. Factors with DAAs treatment failure for chronic hepatitis C-a real-world nationwide HCV Registry Program (TACR) in Taiwan. *Liver International*, 2021; 41: 1265-1277.
92. Liu Z, Derkach A, Yu KJ, Yeager M, Chang YS, Chen CJ, Gyllenstein U, Lan Q, Lee MH, McKay JD, Rothman N, Yang HI, Hildesheim A, Pfeiffer RM. Patterns of human leukocyte antigen class I and class II associations and cancer. *Cancer Research*, 2021; 81 (4): 1148-1152.
93. Liu PC, Chan C, Huang YH, Chen YJ, Liao SF, Lin YJ, Huang C, Lu SN, Jen CL, Wang LY, Yang HI, Shen CY, Chen CJ, Lee MH*. Genetic variants associated with serum alanine aminotransferase levels among patients with hepatitis C virus infection: a genome-wide association study. *J Viral Hepatitis*, 2021; 28 (9): 1265-1273.
94. Huang YH, Hung JY, Ko HW, Su PL, Lai CL, Chang HC, Hsia TC, Lin SH, Wu KL, Yang CT, Su WC, Chu YC, Wang CC, Liao WY, Lin YT, Lin CH, Lin MC, Hsu KH, Tseng JS, Yang TY, Chen KC, Lee MH, Yu SL, Ho CC, Chang GC. The relative importance of

predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. *Ther Adv Med Oncol*, 2021; 13: 1-12.

95. Liao SF, Koshiol J, Huang YH, Jackson SS, Huang YH, Chan C, Huang C, Liu PC, Chen YJ, Hsieh R, Huang JB, Lu SN, Chen CJ, Shen CY, Lee MH*. Postdiagnosis aspirin use associated with biliary tract cancer-specific mortality in a large nationwide cohort. *Hepatology*, 2021; 74 (4): 1994-2006.
96. Lo YH, Cheng HC, Wang HY, Peng CW, Chen CY, Lin KP, Kang ML, Hsiung CN, Chen CH, Chu HW, Shen CY, Lin CF, Lee MH, Liu Q, Satta Y, Lin CJ, Lin M, Chaw SM, Loo JH, Ko WY. Detecting genetic ancestry and adaptation in the Taiwanese Han people. *Molecular Biology and Evolution*, 2021; 38 (10): 4149-65.
97. Liu Z, Huang CJ, Huang YH, Pan MH, Lee MH, Yu KJ, Pfeiffer RM, Viard M, Yuki Y, Gao X, Carrington M, Chen CJ, Hildesheim A, Yang HI. HLA zygosity increases risk of hepatitis B-associated hepatocellular carcinoma. *Journal of Infectious Diseases*, 2021; 224 (10): 1796-1805.
98. Koshiol J, Argirion I, Liu Z, Lam T, O'Brien T, Yu K, McGlynn K, Petrick J, Pinto L, Chen CJ, Hildesheim A, Pfeiffer R, Lee MH, Yang HI. Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-infected individuals. *Aliment Pharmacol Ther*, 2021; 54 (6): 833-842.
99. Lee MH*, Huang YH, Koshiol J. Response letter regarding article, "Postdiagnosis aspirin use associated with biliary tract cancer-specific mortality in a large nationwide cohort." *Hepatology*, 2021; 74 (5): 2925-26.
100. Huang CF, Tseng KC, Cheng PN, Hung CH, Lo CC, Peng CY, Bair MJ, Yeh ML, Chen CH, Lee PL, Lin CY, Kuo HT, Chen CT, Yang CC, Huang JF, Tai CM, Hu JT, Lin CL, Su WW, Tsai WL, Huang YH, Cheng CY, Lin CL, Wang CC, Yang SS, Mo LR, Chen GY, Chang CC, Wang SJ, Huang CS, Hsieh TY, Lin CW, Lee TH, Chong LW, Huang CW, Chang SN, Tsai MC, Hsu SJ, Kao JH, Liu CJ, Liu CH, Lin HC, Lee MH, Tsai PC, Dai CY, Chuang WL, Chen CY, Yu ML. Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: a large cohort study from the nationwide HCV registry program in Taiwan. *Clinical Gastroenterology and Hepatology*, 2021; S1542-3565 (21) 00819-3.

101. Onabajo O, Wang F, Lee MH, Florez-Vargas O, Obajemu A, Tanikawa C, Vargas J, Liao SF, Song C, Huang YH, Shen CY, Banday AR, O'Brien TR, Hu Z, Matsuda K, Prokunina-Olsson L. Intracellular accumulation of IFN- λ 4 induces ER stress and results in anti-cirrhotic but pro-HCV effects. *Frontiers Immunology*, 2021; 12:692263.
102. Argirion I, Pfeiffer RM, Lam TK, O'Brien TR, Yu K, McGlynn KA, Petrick, JL, O, Pinto L, Chen CJ, Lee MH, Hildesheim A, Yang HI, Koshiol J. Association between immunologic markers and cirrhosis in individuals with chronic hepatitis B. *Scientific Reports*, 2021; 11 (1): 21194.
103. Huang CF, Kuo HT, Chang TS, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Chen CY, Tseng KC, Yu ML. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. *Scientific Report*, 2021; 11 (1): 23473.
104. Wang Z, Budhu AS, Shen Y, Wang LL, Hernandez BY, Tiirikainen M, Ma X, Irwin ML, Lu L, Zhao H, Lim JK, Taddei T, Mishra L, Pawlish K, Stroup A, Brown R, Nguyen MH, Koshiol J, Hernandez MO, Forgues M, Yang HI, Lee MH, Huang YH, Iwasaki M, Goto A, Suzuki S, Matsuda K, Tanikawa C, Kamatani Y, Mann D, Guarnera M, Shetty K, Thomas CE, Yuan JM, Khor CC, Koh WP, Risch H, Wang XW, Yu H. Genetic susceptibility to hepatocellular carcinoma (HCC) in chromosome 22q13.31, findings of a genome-wide association study. *JGH Open*, 2021; 5 (12): 1363-72.
105. Cheng PN, Mo LR, Chen CT, Chen CY, Huang CF, Kuo HT, Lo CC, Tseng KC, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Chang TS, Huang JF, Yang CC, Hu JT, Lin CW, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Yang SS, Wu WC, Huang CS, Chou KH, Kao CN, Tsai PC, Liu CH, Lee MH, Cheng CY, Tsai MC, Liu CJ, Dai CY, Lin HC, Kao JH, Chuang WL, Yu ML. Sofosbuvir/Velpatasvir for hepatitis C virus infection: real-world effectiveness and safety from a nationwide registry in Taiwan. *Infect Dis Ther*, 2021; 11 (1): 485-500.
106. Lee MH*, Ahn SH, Chan HLY, Choudhry A, Gani RA, Mohamed R, Ong JP, Shukla A, Tan CK, Tanwandee T, Thuy PTT, Neo BL, Tsang V, Youn J, Singh S. Contextual and

individual factors associated with knowledge, awareness, and attitude on liver diseases: A large-scale Asian Study. *J Viral Hepatitis*, 2022; 29 (2): 156-170.

107. Lo CC, Huang CF, Cheng PN, Tseng KC, Chen CY, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Chang TS, Huang JF, Yang CC, Hu JT, Lin CW, Chen CT, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Mo LR, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Liu CJ, Dai CY, Chuang WL, Lin HC, Kao JH, Yu ML. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: real-world evidence from a nationwide registry in Taiwan. *Journal of the Formosan Medical Association*, 2022; S0929-6646(22)00032-8.
108. Hu HH, WJ Jeng, MH Pan, Luo WS, Chang CL, Huang YT, Su CY, Chiang CT, Jen CL, Chien YC, Lu SN, Wang LY, Huang LR, Lee MH, Liu J, Nguyen MH, Chen CJ, Yang HI. Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis B. *Aliment Pharmacol Ther*, 2022; 55 (5): 558-567.
109. Chen YC, Chang TS, Chen CH, Cheng PN, Lo CC, Mo LR, Chen CT, Huang CF, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Huang JF, Yang CC, Hu JT, Lin CW, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Dai CY, Kao JH, Chuang WL, Lin HC, Chen CY, Tseng KC, Yu ML. Factors associated with significant platelet count improvement in thrombocytopenic chronic hepatitis C patients receiving direct-acting antivirals. *Viruses*, 2022; 14 (2): 333.
110. Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. *Lancet Gastroenterol Hepatol*, 2022; 7 (5): 396-415.
111. Lee MH*. Editorial on “Plasma and breast milk pharmacokinetics of tenofovir alafenamide of mothers with chronic hepatitis B infection”. *Aliment Pharmacol Ther*, 2022; 56: 544-545.
112. Chang TS, Hsu NT, Chen SC, Hsu IL, Lee MH*, Lu SN. Non-B, Non-C hepatocellular carcinoma in an HBV- and HCV-endemic area: A community-based prospective longitudinal study. *Viruses*, 2022; 14 (5): 984.
113. Chou YH, Lin YC, Lee MH, Huang YT, Liu PF, Huang CL, Hu KF. Highly educated

patients have lower dental compliance during the COVID-19 pandemic: an observational study. *BMC Oral Health*, 2022; 22 (1): 284.

114. Argirion I, Brown J, Jackson S, Pfeiffer RM, Lam TK, O'Brien TR, Yu KJ, McGlynn KA, Petrick JL, Pinto L, Chen CJ, Hildesheim A, Yang HI, Lee MH, Koshiol J. Association between immunologic markers and cirrhosis in individuals from a prospective chronic hepatitis C cohort. *Cancers*, 2022; 14 (21): 5280.
115. Lee MH*, Wu PF, Chen TI, Chan C, Lin HH, Huang YH, Chen HY, Lin YT, Chen CJ. Tenofovir use is associated with a decreased risk of hepatocellular carcinoma among men with HIV irrespective of coinfection status. *JHEP Reports*, 2023; 5 (3): 100634.
116. Huang YH, Chan C, Lee HW, Huang C, Chen YJ, Liu PC, Lu SN, Chuang WL, Huang JF, Yu ML, Koshiol J, Lee MH*. Influence of nonalcoholic fatty liver disease with elevated liver enzyme levels on risk of cirrhosis and hepatocellular carcinoma. *Clinical Gastroenterology and Hepatology*, 2023; 21 (4): 960-969.
117. Yu ML, Wang CY, Lee MH, Ou HY, Cheng PN, Tu ST, Huang JF, Chen JF, Hu TH, Hsu CC, Kao JH, Chen CJ, Lin HC, Huang CN. TASL, TADE, and DAROC Consensus for the screening and management of hepatitis C in patients with diabetes. *Journal of the Formosan Medical Association*, 2023; 122 (3): 202-220.
118. Yang TH, Chan C, Yang PJ, Huang YH, Lee MH*. Genetic susceptibility to hepatocellular carcinoma in patients with chronic hepatitis virus infection. *Viruses*, 2023; 15 (2): 559.
119. Chen YJ, Hu KF, Chan C, Huang C, Huang YH, Wang YF, Wang SJ, Chen SP*, Lee MH*. Association of periodontal disease with migraine: a large-scale community-based cross-sectional study. *Headache*, 2023; 63 (4): 539-548.
120. Chang TS, Huang CF, Kuo HT, Lo CC, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Chen CY, Tseng KC, Hung CH, Yu ML. Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry. *Hepatology*, 2023; 77 (3): 550-61.
121. Petrick J, Florio A, Zen J, Wang Y, Gewirtz A, Pfeiffer R, Loftus S, Inglefield J, Koshiol J,

- Yang B, Yu K, Hildesheim A, Chen CJ, Yang HI, Lee MH, McGlynn K. Biomarkers of gut barrier dysfunction and risk of hepatocellular carcinoma in the REVEAL-HBV and REVEAL-HCV cohort studies. *Int J Cancer*, 2023; 153 (1): 44-53.
122. Huang CW, Lee KY, Lin PT, Nian FS, Cheng HY, Chang CH, Liao CY, Su YL, Seah C, Li C, Chen YF, Lee MH, Tsai JW. Muscleblind-like 2 knockout shifts adducin 1 isoform expression and alters dendritic spine dynamics of cortical neurons during brain development. *Neuropathy and Applied Neurobiology*, 2023; 49 (2): e12890.
123. Lin HC, Liu J, Pan MH, Lee MH, Batrla-Utermann R, Lu SN, Jeng WJ, Yang HI, Chen CJ. Rapid decline rather than absolute level of HBsAg predicts its seroclearance in untreated chronic hepatitis B patients from Taiwanese communities. *Clinical Translational Gastroenterology*, 2023.
124. Razavi HA, Buti M, Terrault NA, Zeuzem S, Yurdaydin C, Tanaka J, Aghemo A, Akarca US, Al Masri NM, Alalwan AM, Aleman S, Alghamdi AS, Alghamdi S, Al-Hamoudi WK, Aljumah AA, Altraif IH, Asselah T, Ben-Ari Z, Berg T, Biondi MJ, Blach S, Braga WSM, Brandão-Mello CE, Brunetto MR, Cabezas J, Cheinquer H, Chen PJ, Cheon ME, Chuang WL, Coffin CS, Coppola N, Craxi A, Crespo J, De Ledinghen V, Duberg AS, Etzion O, Ferraz MLG, Ferreira PRA, Forns X, Foster GR, Gaeta GB, Gamkrelidze I, García-Samaniego J, Gheorghe LS, Gholam PM, Gish RG, Glenn J, Hercun J, Hsu YC, Hu CC, Huang JF, Janjua N, Jia J, Kåberg M, Kaita KDE, Kamal H, Kao JH, Kondili LA, Lagging M, Lázaro P, Lazarus JV, Lee MH, Lim YS, Marotta PJ, Navas MC, Naveira MCM, Orrego M, Osiowy C, Pan CQ, Pessoa MG, Raimondo G, Ramji A, Razavi-Shearer DM, Razavi-Shearer K, Ríos-Hincapié CY, Rodríguez M, Rosenberg WMC, Roulot DM, Ryder SD, Safadi R, Sanai FM, Santantonio TA, Sarrazin C, Shouval D, Tacke F, Tergast TL, Villalobos-Salcedo JM, Voeller AS, Yang HI, Yu ML, Zuckerman E. Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries. *Journal of Hepatology*, 2023; 79 (2): 576-580.
125. Huang JF, Tsai PC, Yeh ML, Huang CF, Huang CI, Lee MH, Hsu PY, Wang CW, Wei YJ, Liang PC, Lin YH, Hsieh MH, Yang JF, Hsieh MY, Jang TY, Bair MJ, Lin ZY, Dai CY, Yu ML, Chuang WL. Community-centered disease severity assessment of metabolic dysfunction-associated fatty liver disease. *Journal of Clinical and Translational Hepatology*, 2023; 11 (5): 1061-1068.
126. O'Brien TR, Lee MH, Wilson E, Kottlilil S. *IFNL4* Genotype Frequencies in Asian

Populations Support Shorter Duration Therapy with Sofosbuvir-Based Hepatitis C Virus Regimens to Increase the Number Cured. *J Interferon Cytokine Res*, 2023.

127. Hsu C, Gopalakrishna H, Mironova M, Lee MH, Chen CJ, Yang HI, Wiese M, Chang KM, Wright EC, Abijo T, Feld J, Kaplan D. Risk of hepatocellular carcinoma after spontaneous clearance of hepatitis C virus and in non-cirrhosis chronic hepatitis C patients with sustained virological response: A systematic review. *Clin Inf Dis*, 2023; 77 (S3): S245-256.
128. Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modeling study. *Lancet Gastroenterol Hepatol*, 2023; S2468-1253.
129. Lee MH. Reply:
130. Lai JI, Kuo TH, Huang KJ, Chai LMX, Lee MH, Liu CY, Tsai YF, Huang CC, Tseng LM, Hsu CC, Chao TC. Clinical and genotypic insights into higher prevalence of Palbociclib associated neutropenia in Asian patients. *Oncologist*, 2023; doi: 10.1093/oncolo/oyad304.
131. Chang SL, Lai CH, Lin GC, Chen YM, Lee MH, Hsu HS, Chen IC. Genetic susceptibility of HLA alleles to non-steroidal anti-inflammatory drug hypersensitivity in the Taiwanese population. *Biomedicines*, 2023. doi: 10.3390/biomedicines11123273
132. Tsai MH, Ke HC, Lin WC, Nian FC, Huang CW, Cheng HY, Hsu CS, Granata T, Chang CH, Catellotti B, Lin SY, Doniselli FM, Lu CJ, Franceschetti S, Ragona F, Hou PS, Canafoglia L, Tung CY, Lee MH, Wang WJ, Tsai JW. Novel lissencephaly-associated NDEL1 variant reveals distinct roles of NDE1 and NDEL1 in nucleokinesis and human cortical malformations. *Acta Neuropathologica*, 2024; 147 (1): 13.
133. Huang YH, Loftfield E, Argirion I, Adami H, Albanes D. Chan AT, Fedirko V, Fraser GE, Freedman ND, Giles GG, Hartge P, Katzke V, Knutsen SF, Lacey JJ, Liao LM, Luo J, Milne RL, O'Brien KM, Peters U, Poynter JN, Purdue MP, Robien K, Sandin S, Sandler DP, Setiawan VW, Kang JH, Simon TG, Sinha R, VoPham T, Weinstein SJ, White E, Zhang X, Bin Z, McGlynn, KA, Campbell PT, Lee MH^{*}, Koshiol J^{*}. Association of tea and coffee consumption and biliary tract cancer risk: The biliary tract cancers pooling project. *Hepatology*, 2024; 79 (6): 1324-1336.
134. Tsai MH, Lin WC, Chen SY, Hsieh MY, Nian FS, Cheng HY, Zhao HJ, Hung SS, Hsu CH, Hou PS, Tung CY, Lee MH, Tsai JW^{*}. Lissencephaly-associated BAIAP2 variant causes defects in neuronal migration during brain development. *Development*, 2024; 151

(2): dev201912.

135. Lee MH^{*}, Chen YT, Huang YH, Lu SN, Yang TH, Yin SC, Yeh ML, Huang CF, Dai CY, Chuang WL, Yu ML, Yang HI, Chen HY, Chen CJ. Chronic viral hepatitis B and C outweigh MASLD in the associated risk of cirrhosis and HCC. *Clin Gastrol Hepatol*, 2024; 22 (6): 1275-1285.
136. Lin HC, Jeng WJ, Liu J, Pan MH, Lee MH, Batrla-Utermann R, Lu SN, Chen CF, Yang HI, Chen CJ. Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients. *Aliment Pharmacol Ther*, 2024; 59 (8): 993-1002.
137. Chen YT, Chen TI, Yang TH, Yin SC, Lu SN, Liu XR, Gao YZ, Lin CJ, Huang CW, Huang JF, Yeh ML, Huang CF, Dai CY, Chuang WL, Yang HI, Yu ML, Lee MH^{*}. Long-term risks for cirrhosis and hepatocellular carcinoma across steatotic liver disease subtypes. *Am J Gastrol*, 2024; 119 (11): 2241-2250.
138. Yeh ML, Dai CY, Huang CF, Huang SF, Tsai PC, Hsu PY, Huang CI, Wei YJ, Liang PC, Bair MJ, Lee MH, Lin ZY, Huang JF, Yu ML, Chuang WL. The efficacy of multi-disciplinary lifestyle modifications in Taiwanese non-alcoholic steatohepatitis patients. *Kaohsiung J Med Sci*, 2024; 40 (6): 575-582.
139. Yang CC, Huang CF, Chang TS, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Kuo HT, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Tseng KC, Chen CY, Yu ML. Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan. *Infect Dis Ther*. 2024;13(6):1199-1213.
140. Jang TY, Huang CF, Chang TS, Yang CC, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Tseng KC, Chen CY, Kuo HT, Yu ML. Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic

- hepatitis C patients -a nationwide Taiwan HCV registry. *J Formos Med Assoc.* 2024; S0929-6646(24)00381-4.
141. Chen YT, Chen TI, Yin SC, Huang CW, Huang JF, Lu SN, Yeh ML, Huang CF, Dai CY, Chen YW, Chuang WL, Yu ML, Lee MH*. Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with MASLD. *JGH*, 2024; 39 (9): 1939-1949.
 142. Chang SH, Su TH, Ling ZM, Lee MH, Liu CJ, Chen PJ, Yang HC, Liu CH, Chen CL, Tseng TC, Chen CH, Lee HS, Chen CJ, Kao JH. Fibrosis-4 index stratifies risks of hepatocellular carcinoma in patients with chronic hepatitis C. *J Formos Med Assoc.* 2024;123(11):1154-1160.
 143. Huang JF, Chang TJ, Yeh ML, Shen FC, Tai CM, Chen JF, Huang YH, Hsu CY, Cheng PN, Lin CL, Hung CH, Chen CC, Lee MH, Lee CC, Lin CW, Liu SC, Yang HI, Chien RN, Kuo CS, Peng CY, Chang ML, Huang CF, Yang YS, Yang HC, Lin HC, Ou HY, Liu CJ, Tseng CH, Kao JH, Chuang WL, Huang CN, Chen PJ, Wang CY, Yu ML. Clinical care guidance in patients with diabetes and metabolic dysfunction–associated steatotic liver disease: A joint consensus. *Hepatology Communications*, 2024; 8 (11): e0571
 144. Su TH, Yang SS, Lee MH, Kao WY, Huang SC, Chen FF, Poon FSK, Tsai LW, Chen YT, Lin C, Wang W, Kim WR, Kao JH. High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease. *Clin Mol Hepatol.* 2025; 31 (3): 796-809.
 145. Polaris Observatory Collaborators. The number of people treated for hepatitis C virus infection in 2014-2023 and applicable learnings for new HBV and HDV therapies. *J Hepatol.* 2025; 83 (2): 329-347.
 146. Zhang T, Huang CJ, Chen HT, Huang YH, Pan MH, Lee MH, Viard M, Hildesheim A, Pfeiffer RM, Carrington M, Chen CJ, Zhu B, Lenz TL, Jiang D, Yang HI, Liu Z. *HLA-DQB1*03:01* and risk of Hepatitis B virus-related hepatocellular carcinoma. *Hepatology.* 2025
 147. Chen TI, Chen MH, Yin SC, Lin CJ, Lam TK, Huang CW, Chen YT, Liu XR, Gao YZ, Hsu WL, Chen HY, Yeh TS, Koshiol J, Lee MH*. Association between metabolic syndrome and cholangiocarcinoma risk: a large-scale population-based cohort study. *Hepatology.* 2025
 148. Liu XR, Yin SC, Chen YT, Lee MH*. Metabolic dysfunction-associated steatotic liver

disease and its associated health risks. *Journal of Chinese Medical Association*, 2025; 88 (5): 343-351.

149. Yin SZ, Chen MS, Chang WT, Chen TI, Yang TH, Liu XR, Huang CW, Chen YW, Lee MH^{*}. Attributable burden of steatotic liver disease on cardiovascular outcomes in Asia. *JHEP Reports*, 2025

Books or Chapters

- ♦ Lee MH. 2011. Chapter 9: Gallbladder cancer. In: Chen CJ, Chen KY (eds.) Epidemiological characteristics and preventive strategies of cancers in Taiwan. S.Y. Tao Cancer Prevention Foundation, Taiwan, pp. 69-73. (in Chinese)
- ♦ Chen CJ, Hsu WL, Yang HI, Lee MH, Chen HC, Chien YC, You SL. 2013. Epidemiology of virus infection and human cancer. In: Chang MH: Viruses and Human Cancer. Springer-Verlag Berlin Heidelberg, New York, USA
- ♦ Liu J, Yang HI, Lee MH, Hsu WL, Chen HC, Chen CJ. 2015. Epidemiology of virus infection and human cancer. In: Michael R. Surin, Yasmin Thanavala, Iahed Ismail: Infection and Cancer: Bi-directorial Interactions. Springer Cham Heidelberg New York Dordrecht London
- ♦ Chen CJ, Yang HI, Lee MH, Liu J, Hu HH. 2015. Natural History of HBV Infection in the Community. In Yun-Fan Liaw and Fabien Zoulim: Hepatitis B Virus and Human Diseases. Springer.
- ♦ Yang HI, Lee MH, Liu J, Hu HH. Epidemiology of Viral Hepatitis B, C, and D: A Global View. 2019. Viral Hepatitis in Children, pp33-53. Springer. DOI: 10.1007/978-981-13-0050-9_3